Wells Fargo analyst Jacob Hughes says Flexion Therapeutics remains of his firm's best ideas after the FDA approved a revised label for Zilretta. This is "very encouraging news" from both a sentiment and longer-term peak sales perspective, Hughes tells investors in a research note. The analyst reminds investors that a recent Wells Fargo physician showed that 67% of those surveyed said the removal of the not intended for repeat administration language would have an impact on their prescribing behavior for Zilretta. Hughes keeps an Overweight rating on Flexion shares.